To evaluate the importance of CXCL1/2 and CFB in driving NET formation under treatments, we applied Dox in combination with SB225002 or LNP023, the inhibitors of CXCR2 (the co-receptor of CXCL1/2) or CFB, respectively, in orthotopic 4T1 and MCF-7 tumor model (Figure 3K and Supplemental Figure 7A) (29, 30). This evidence concerns the gene CFB and neoplasm.